⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
globenewswire.com
AIM
AIM ImmunoTech Announces Stock Dividend
globenewswire.com
AIM
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
prnewswire.com
ONCY
AVBP
MRUS
HALO
AIM
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
globenewswire.com
AIM
AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
globenewswire.com
AIM
Impact Communications Clients Shine as 2025 ThinkAdvisor Luminaries Award Finalists
businesswire.com
ADVV
AIM
SYNTAX
OASIS
LIBRETTO
KWANTI
STRAIGHTLINE
ENCORE
AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
globenewswire.com
AIM
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
globenewswire.com
AIM
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
globenewswire.com
AIM
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
globenewswire.com
AIM